Persistent URL of this record https://hdl.handle.net/1887/107524
In Collections
This item can be found in the following collections:
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
- All authors
- Pollack, C.V.; Reilly, P.A.; Bernstein, R.; Dubiel, R.; Eikelboom, J.; Glund, S.; Huisman, M.V.; Hylek, E.; Kam, C.W.; Kamphuisen, P.W.; Kreuzer, J.; Levy, J.H.; Sellke, F.; Stangier, J.; Steiner, T.; Wang, B.S.; Weitz, J.I.
- Date
- 2015-07-31
- Journal
- Thrombosis and Haemostasis
- Volume
- 114
- Issue
- 1
- Pages
- 198 - 205